105 indexable Life Sciences companies headquartered in Vienna, Austria, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $781.8M across 33 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Flinn
AI-enabled solution for manufacturers to automate compliance processes |
$11.2M | — | Series A | Series A Feb 2026 | — | 2022 | ↑ Active |
| 2 |
HOOKIPA Pharma
Developer of immunotherapies for the treatment of infectious diseases and cancer |
$133.7M | — | Public | Post IPO Dec 2023 | 132 | 2011 | — |
| 3 |
invIOs
Developer of immunotherapies for the treatment of cancer |
$9M | — | Series A | Series A Oct 2024 | — | 2019 | ↑ Active |
| 4 |
Turn-Motion
Developer of AI-powered platform for designing and manufacturing custom orthoses |
$1.3M | — | Funding Raised | Grant (prize money) Mar 2025 | — | 2022 | ↑ Active |
| 5 |
YGION
Developer of immunotherapies for the treatment of cancer |
$16.3M | — | Series A | Series A May 2024 | — | 2022 | — |
| 6 |
HELLO INSIDE
Provider of continuous glucose monitoring sensors and related mobile application |
$1.8M | — | Seed | Seed Sep 2024 | 19 | 2021 | ↑ Active |
| 7 |
Nabriva
Developer of pleuromutilin class of antibiotics for MDR infections |
$193.1M | — | Public | Conventional Debt Dec 2018 | 39 | 2006 | — |
| 8 |
Themis Bioscience
Prophylactic vaccines for infectious diseases |
$82.5M | — | Acqui-Hired | Series D Sep 2019 | 40 | 2009 | — |
| 9 |
AFFiRiS
Developer of therapeutics for neurodegenerative diseases |
$82.6M | — | Series B | Series B May 2017 | 10 | 2003 | — |
| 10 |
HeartBeat
Developer of stem-cell derived organoid models for cardiac drug discovery |
$6.6M | — | Seed | Seed Nov 2023 | 14 | 2021 | — |
| 11 |
Ribbon Biolabs
Developer of a technology platform for the synthesis of long DNA molecules |
$20.1M | — | Series A | Series A Jan 2022 | 38 | 2017 | — |
| 12 |
Intercell
Developer of vaccines for infectious diseases (merged with Vivalis {France} to form Valneva in 2012) |
$78.6M | — | Acquired | Series B Feb 2011 | — | 1998 | — |
| 13 |
Nagene
Provider of gene synthesis solutions for customized DNA sequences |
$1.8M | — | Seed | Apr 2024 | — | 2023 | — |
| 14 |
Igeneon
Cancer Immunotherapy drug discovery company acquired by Aphton in 2004, deadpooled in 2006 |
$59.9M | — | Deadpooled | Feb 2004 | — | 1999 | — |
| 15 |
Apeiron Biologics
Developer of tumour targeting antibodies and small molecule immunotherapeutics for the treatment of cancer |
$29.9M | — | Acquired | PE May 2020 | 14 | 2005 | — |
| 16 |
Platomics
Marketplace provider for the genomic test-based personalized medicines |
$16.4M | — | Series A | Series A Sep 2021 | 48 | 2011 | — |
| 17 |
imd Biotech
Developer of diagnostic equipment for biomolecule detection and measurement |
$430.8K | — | Seed | Angel May 2024 | — | 2020 | — |
| 18 |
Marinomed
Developer of drugs for immunology, allergy and infectious diseases |
$6.3M | — | Public | Post IPO Oct 2021 | 44 | 2006 | — |
| 19 |
Allcyte
Developer of drugs for the treatment of cancer patients |
$6M | — | Acquired | Seed Mar 2021 | 30 | 2017 | — |
| 20 |
EveliQure Biotechnologies
Developing a vaccine against Diarrhea using a proprietary technology platform |
$5.5M | — | Funding Raised | Grant (prize money) Sep 2019 | 7 | 2012 | — |
| 21 |
Evercyte
Cell lines, reagents and research services for pharma and cell therapies |
$1M | — | Funding Raised | Grant (prize money) Sep 2022 | 7 | 2011 | — |
| 22 |
TissueGnostics
Provider of instruments and software for digital pathology |
$984.3K | — | Public | Grant (prize money) Sep 2022 | — | 2003 | — |
| 23 |
mySugr
Gamification apps for diabetes management and therapy |
$4.8M | — | Acquired | Seed Mar 2015 | 130 | 2012 | — |
| 24 |
a:head bio
Developer of therapeutics based on human cerebral organoids for brain disorders |
$2.8M | — | Funding Raised | Grant (prize money) Oct 2019 | 15 | 2018 | — |
| 25 |
Zytoprotec
Develops cytoprotective therapies for the treatment of end-stage renal disease (ESRD) and other diseases |
$2.9M | — | Series A | Grant (prize money) Jan 2019 | 10 | 2007 | — |
| 26 |
PhagoMed
Company developing alternatives to antibiotics through their expertise in phage therapy |
$1.7M | — | Acquired | Seed Jul 2019 | 14 | 2016 | — |
| 27 |
Akribes Biomedical
Developing new drugs against chronic wounds using proprietary assays |
$294.6K | — | Funding Raised | Grant (prize money) Jan 2023 | — | 2015 | — |
| 28 |
Panoptes Pharma
Small molecule drugs to treat eye diseases |
$1.6M | — | Acqui-Hired | Series A Nov 2015 | 5 | 2013 | — |
| 29 |
Ivary
At-home diagnostic kits to assess the ovarian reserve |
$1.3M | — | Deadpooled | Seed Feb 2017 | — | 2014 | — |
| 30 |
Engenes
Developer of recombinant proteins |
$773.2K | — | Funding Raised | Grant (prize money) Jan 2018 | — | 2014 | — |
| 31 |
TAmiRNA
Provider of microRNA-based diagnostics and therapeutics targeting age-associated disorders |
$427.2K | — | Funding Raised | Grant (prize money) Oct 2019 | 14 | 2014 | — |
| 32 |
ViennaLab Diagnostics
Develops membrane-based reverse hybridization tests for DNA variants diagnosis |
$112.7K | — | Funding Raised | Grant (prize money) Jan 2020 | — | 1990 | — |
| 33 |
The Antibody Lab
Company developing immunoassays and preclinical biologics through their proprietary antibody engineering and protein expression technologies |
$110.2K | — | Funding Raised | Grant (prize money) Oct 2015 | — | 2014 | — |
| 34 |
Novasign
Provider of modeling solutions to accelerate bioprocess development |
— | — | Seed | Seed Sep 2025 | 8 | 2019 | ↑ Active |
| 35 |
CellEctric Biosciences
Developer of a technology for detection of sepsis |
— | — | Funding Raised | Grant (prize money) Jun 2024 | 15 | 2021 | — |
| 36 |
Syntropic
Medical device company developing treatment for mental health disorders through light stimulation |
— | — | Seed | Seed Apr 2024 | — | 2023 | — |
| 37 |
BiomeDx
Developer of personalines diagnostic tool for cancer care |
— | — | Seed | Seed Jun 2023 | 16 | 2020 | — |
| 38 |
QUANTRO Therapeutics
Developer of transcriptional fingerprinting therapeutic solutions for drug discovery |
— | — | Seed | Seed Jul 2020 | 16 | 2020 | — |
| 39 |
Lexogen
Provider of kits and software that enable detailed analysis of the complete transcriptome |
— | — | Late Stage | PE Apr 2020 | 76 | 2007 | — |
| 40 |
Ares Genetics
Provider of DNA-based precision medicine for infectious diseases |
— | — | Seed | Seed Jan 2019 | 21 | 2017 | — |
| 41 |
OncoQR
Adjustable cancer immunotherapies (ACIs) to treat oncologic diseases. |
— | — | Funding Raised | Grant (prize money) 2016 | — | 2013 | — |
| 42 |
OncoLab Diagnostics
Developer of RNA biomarker-based tests for cancer detection |
— | — | Funding Raised | Grant (prize money) 2015 | 4 | 2006 | — |
| 43 |
Origimm
Biotech company focused on antigen and drug target discovery for prevention and treatment of dermatological/infectious conditions |
— | — | Acqui-Hired | Seed May 2014 | 12 | 2014 | — |
| 44 |
S-TARget therapeutics
Early-stage biotech company developing therapeutic vaccines for allergic diseases |
— | — | Funding Raised | Grant (prize money) Dec 2009 | — | 2009 | — |
| 45 |
Ablevia
Developer of therapeutics for selective antibody removal |
— | — | Funding Raised | — | 3 | 2018 | — |
| 46 |
Activartis Biotech
Personalised dendritic cell-based therapies for the treatment of cancers such as brain. |
— | — | Deadpooled | — | — | 2003 | — |
| 47 |
Algonist Biotechnologies
Developer of drugs for chronic pain management |
— | — | Funding Raised | — | 5 | 2020 | — |
| 48 |
Alpha Trace
Diagnostics and monitoring systems for hospitals |
— | — | Unfunded | — | — | 1980 | — |
| 49 |
AOP Health
Developer of treatments for rare diseases |
— | — | Unfunded | — | 450 | 1996 | — |
| 50 |
Aposcience
Developing therapeutics from PMBC secretome to heal wounds and ischemia-induced inflammation |
— | — | Unfunded | — | — | 2008 | — |
AI-enabled solution for manufacturers to automate compliance processes. It empowers medical device manufacturers to automate compliance processes to launch and operate high-quality products.
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
Developer of immunotherapies for the treatment of cancer. The company has a proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enabling rapid treatment of patients using their own cells. The lead candidate of the company is APN401 for the treatment of solid tumors. Other drug candidates include INV441 and INV501, an early-stage cell therapy approach to activate tu
Developer of AI-powered platform for designing and manufacturing custom orthoses. It provides a system that integrates AI, automation, and fiber technology to produce precision-fit orthotics. The platform captures patient data via an application, uses AI to optimize the structural design, and automates the production process. This enables orthopedic technicians and medical supply stores to streamline orthotic care, r
Developer of immunotherapies for the treatment of cancer. The company has YGNITE platform that combines next generation sequencing, bioinformatics and the proprietary CARGONAUT vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient.
Provider of continuous glucose monitoring sensors and related mobile application. The company offers tools for individuals to track blood sugar levels and understand metabolic responses. The application provides personalized recommendations based on user data, aiming to promote sustainable lifestyle changes. The offering includes educational programs designed to help users achieve health goals.
Nabriva Therapeutics is developing pleuromutilin class of antibiotics for MDR infections. Its lead product candidate is Lefamulin for treating acute bacterial skin and skin structure infections (phase II); intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) (FDA approved); for pediatric indications (phase I), STI, osteomyelitis, HABP/VABP, and prosthetic joined infecti
Themis Bioscience is focussed on developing prophylactic vaccines for infectious diseases. It is using its proprietary Themaxyn platform to identify and advance its vaccine candidates at various stages of development. It has initial vaccine candidates currently in development for chikungunya and dengue fever. The company has developed cancer therapies using a measles vector, such as adding different tumour killing an
AFFiRiS is developing the therapeutics for neurodegenerative diseases. The technology called antigen-specific peptide vaccines is used for the prevention and treatment of Parkinson's diseases, Huntington diseases, and multiple system atrophy among others. The company's proprietary AFFITOME Technology delivers peptides that induce an immune response where the generated antibodies target the proteins. Currently, the co
Developer of stem-cell-derived organoid models for cardiac drug discovery. The company has a high-throughput 3D screening platform based on cardiac organoids for cardiovascular drug discovery.
Developer of a technology platform for the synthesis of long DNA molecules. The company uses genetic solutions by the high-throughput synthesis of DNA. The company is focusing on libraries of DNAs of lengths of up to thousands of base pairs. The company is building genomes, high-throughput libraries, along with providing new products based on DNA, storing data, computing with DNA, and building DNA-based nanotechnolog
Intercell was developing vaccines for infectious diseases. It developed antigens and adjuvants for vaccines. In Dec 2012, Vivalis acquired Intercell for $174M, and the combined entity was renamed Valneva. The company had a vaccine for Japanese encephalitis in the market at the time of its acquisition.
Europa
INiTS
FFG
Austria Wirtschaftsservice
Arax Capital Partners
EIT Health
Vienna Business Agency
BioVaria
EIC Fund
ILUM Tec
aws Grunderfonds
xista
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-21.
_1553572681956.png){kind=logo}
_1581929172265.png){kind=logo}
_1591704760237.png){kind=logo}
